Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com
StockNews.com assumed coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Free Report) in a report issued on Friday morning. The firm issued a sell rating on the biotechnology company’s stock. Separately, Roth Capital lowered Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Get Our Latest […]
More Stories
900 Visas Revoked in Birth Tourism Crackdown: State Department
By Jack Phillips The U.S. Department of State on Aug. 20 said that nearly 900 visas have been revoked since...
A Man on the Inside: Release Date, Trailer, Plot, and Episode Updates
Is your favourite detective, Ted Danson, returning with a season 3 of A Man on the Inside? Fans are looking...
8 Killed After Charter Plane Crashes in Western Alaska: US Military
By AldgraFredly The U.S. military said on Aug. 20 that eight people were killed after a charter plane crashed at...
Israel, Turkey Continue Dispute Over Syria After Airbase Strike
By Evgenia Filimianova Israel and Turkey have deepened their dispute over Syria after Israel defended its strike on a Syrian...
First Lady Unveils Racing Collaboration, $2 Million in ‘Fostering the Future’ Scholarships
By Travis Gillmore WASHINGTON—First Lady Melania Trump held her first public event in about two months at the White House...
US Unemployment Claims Unexpectedly Dropped Last Week
By Andrew Moran The number of Americans submitting applications for unemployment benefits unexpectedly declined last week for the first time...